NDAORALTABLETPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
109
Data completeness
6/8 — Strong
Priority Review
VENCLEXTA (venetoclax) by AbbVie is p-glycoprotein inhibitors [moa]. Approved for chronic lymphocytic leukemia, small lymphocytic lymphoma, acute myeloid leukemia. First approved in 2016.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VENCLEXTA (venetoclax) is an oral BCL-2 inhibitor approved by the FDA in April 2016 for the treatment of hematologic malignancies. The drug works by inhibiting B-cell lymphoma 2 (BCL-2) protein, promoting apoptosis in cancer cells. While the specific indications are not detailed in the provided data, venetoclax is established as a key agent in treating chronic lymphocytic leukemia and other blood cancers, representing an important addition to the precision oncology treatment landscape.
$0.8BPart D
7.3 years to LOEMechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
BCL-2 Inhibitor
Indications (3)
Worked on VENCLEXTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.